Cyclin-Dependent Kinase 6
"Cyclin-Dependent Kinase 6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 6 associates with CYCLIN D and phosphorylates RETINOBLASTOMA PROTEIN during G1 PHASE of the CELL CYCLE. It helps regulate the transition to S PHASE and its kinase activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P18.
| Descriptor ID |
D051361
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.937 D12.644.360.250.515 D12.776.167.200.515 D12.776.476.250.515
|
| Concept/Terms |
Cyclin-Dependent Kinase 6- Cyclin-Dependent Kinase 6
- Cyclin Dependent Kinase 6
- Cell Division Protein Kinase 6
- Cdk6 Protein Kinase
- Protein Kinase, Cdk6
- CDK6 Protein
- PLSTIRE Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 6".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 6".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 6" by people in this website by year, and whether "Cyclin-Dependent Kinase 6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 6" by people in Profiles.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022 May; 113(5):1808-1820.
-
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat Commun. 2018 12 05; 9(1):5200.
-
Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype. Cancer. 2018 02 01; 124(3):636-647.
-
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5561-5572.
-
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. Clin Cancer Res. 2017 Jun 01; 23(11):2856-2868.
-
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016 04 15; 76(8):2301-13.
-
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. Mol Cancer Ther. 2016 Jan; 15(1):94-105.
-
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell. 2012 Oct 16; 22(4):452-65.
-
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila). 2011 Dec; 4(12):2051-61.